DDInter1939 DDInter596
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug.
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Vinorelbine {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Vinorelbine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Vinorelbine {u} (Compound) upregulates {v} (Gene) DHCR7
DHCR7 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Vinorelbine {u} (Compound) downregulates {v} (Gene) DNAJC4
DNAJC4 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Vinorelbine {u} (Compound) upregulates {v} (Gene) RELB
RELB {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Vinorelbine {u} (Compound) upregulates {v} (Gene) JMJD6
JMJD6 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Vinorelbine {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Vinorelbine {u} (Compound) causes {v} (Side Effect) Infestation NOS
Infestation NOS {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Vinorelbine {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Vinorelbine (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Doxorubicin (Compound)
Vinorelbine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxorubicin (Compound)
Vinorelbine (Compound) upregulates DHCR7 (Gene) and DHCR7 (Gene) is bound by Doxorubicin (Compound)
Vinorelbine (Compound) downregulates DNAJC4 (Gene) and DNAJC4 (Gene) is upregulated by Doxorubicin (Compound)
Vinorelbine (Compound) upregulates RELB (Gene) and RELB (Gene) is upregulated by Doxorubicin (Compound)
Vinorelbine (Compound) upregulates JMJD6 (Gene) and JMJD6 (Gene) is downregulated by Doxorubicin (Compound)
Vinorelbine (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Doxorubicin (Compound)
Vinorelbine (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Doxorubicin (Compound)
Vinorelbine (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Doxorubicin (Compound) and TOP2A (Gene) is downregulated by Doxorubicin (Compound)